SCHEMBL4755626

SCHEMBL4755626

CNC(=O)C=Cc1cccs1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.69
SMN1; SMN2 Q16637 7/20 0.63
HPGD P15428 3/20 0.63
HCAR2 Q8TDS4 1/20 0.62
NPC1 O15118 5/20 0.61
RAB9A P51151 5/20 0.61
MAPT P10636 2/20 0.61
HTT P42858 2/20 0.61
KMT2A Q03164 2/20 0.61
KDM4E B2RXH2 2/20 0.60
MEN1 O00255 1/20 0.60
PSMD14 O00487 1/20 0.60
TP53 P04637 1/20 0.60
GLA P06280 1/20 0.60
TAS1R3 Q7RTX0 1/20 0.60
TAS1R1 Q7RTX1 1/20 0.60
ALDH1A1 P00352 4/20 0.59
GAA P10253 1/20 0.58
POLB P06746 1/20 0.57
GAPDH P04406 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426063 0.84 LMNA (0.66) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL9853158 0.84 LMNA (0.66) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL8194585 0.82 LMNA (0.64) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL8194587 0.82 LMNA (0.64) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL28887946 0.81 MAPT (0.74) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL7749569 0.80 SMN1; SMN2 (0.69) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL1862223 0.79 HCAR2 (0.69) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL369705 0.79 HCAR2 (0.69) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL5598744 0.79 HCAR2 (0.74) LMNASMN1; SMN2HPGDHCAR2NPC1
SCHEMBL5598741 0.79 HCAR2 (0.74) LMNASMN1; SMN2HPGDHCAR2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1411045-B1 Process for production of optically active amino alcohols YOKOZAWA TOHRU (JP) 2008-01-16 EP claimed
EP-0146277-B1 CELLULOSIC PRODUCTS A.E. STALEY MANUFACTURING COMPANY (US) 1990-11-14 EP claimed
EP-4263511-A1 NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION Amphista Therapeutics Ltd (GB) 2023-10-25 EP disclosed
CN-116897150-A Novel bifunctional molecules for protein-targeted degradation 安菲斯塔治疗有限公司 2023-10-17 CN disclosed
WO-2022129925-A1 NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2022-06-23 WO disclosed
US-9079931-B2 Ruthenium complex and method for preparing optically active alcohol compound TAKASAGO INTERNATIONAL CORPORATION (JP) 2015-07-14 US disclosed
EP-2563799-B1 RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND TAKASAGO PERFUMERY CO LTD (JP) 2015-02-11 EP disclosed
US-20130041151-A1 RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-02-14 US disclosed
EP-1411045-B1 Process for production of optically active amino alcohols YOKOZAWA TOHRU (JP) 2008-01-16 EP disclosed
US-6984738-B2 Process for production of optically active amino alcohols YOKOZAWA TOHRU 2006-01-10 US disclosed
US-20040082794-A1 Process for production of optically active amino alcohols YOKOZAWA TOHRU (JP) 2004-04-29 US disclosed
EP-1411045-A1 Process for production of optically active amino alcohols Yokozawa, Tohru (JP) 2004-04-21 EP disclosed
EP-0146277-B1 CELLULOSIC PRODUCTS A.E. STALEY MANUFACTURING COMPANY (US) 1990-11-14 EP disclosed
EP-0146277-A2 Cellulosic products A.E. STALEY MANUFACTURING COMPANY (US) 1985-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041151-A1 RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND ADH5, ADH1C, ADH1A LMNA 4045/4885SMN1; SMN2 4807/4885HPGD 757/4885
US-20040082794-A1 Process for production of optically active amino alcohols ADH5, ADH1C, ADH1A LMNA 3886/4885SMN1; SMN2 4253/4885HPGD 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.